Wednesday November 28

West Coast Day 1

The Big Picture

Dr Richard Pan

Keynote Opening Address: The impact of vaccine legislation on public health in California

Panel discussion

Addressing the epidemic of misinformation

  • What are the key drivers of hesitancy to vaccinate?
    • Complacency, convenience and confidence
  • What works in tackling misinformation and building trust?
    • E.g. what steps are being taken to counteract sophisticated social media campaigns of parent groups?
  • What responsibility do public health and education authorities have and how can companies get involved?
Dr Shane Crotty

How T cells control antibody responses: T follicular helper (Tfh) CD4 T cells and germinal center B cell responses to vaccines

Panel discussion

The evolution of antibody therapy for cancer

  • Progress in the development of antibody drug conjugates,bispecific antibodies, and fusion protein/antibodies
  • Novel approaches in antibody therapy- who is leading the next generation of antibody development?
  • What have been the most successful and least successful antibody therapies? Why?
  • How do we decide what level of toxicity is acceptable? Does this vary across indications?

Morning Networking Break & Poster Session

Respiratory Diseases

Cancer Vaccine Development

Trial design and analysis

Clinical Trials

Designing innovative cohort adaptive sequential trials in oncology and other therapeutic areas

  • How can innovative trial design help speed the development process and make it more accurate?
  • Using one trial to address and identify the benefitting patient subpopulation
Vaccine Development

Plant-derived VLPs as a Novel Approach to Addressing Unmet Needs in Influenza Prevention

  • Advanced clinical development of a plant-derived quadrivalent VLP vaccine in adults and the elderly
Clinical Trials

Lung- MAP: using state-of-the-art genomic profiling to match patients to the most appropriate clinical trial

  • Overview of umbrella trials
  • What are the advantages of using this type trial design?
    • Reduction of cost, patient access, accelerated development
  • Efforts to create an immunotherapy clinical trial platform within the trial design to allow for running of multiple studies at the same time.

Tools to identify, predict and prioritize vaccine candidates

  • Clinical challenges in cancer immunotherapy.
  • Personalized cancer vaccines have the potential to enhance the efficacy of checkpoint inhibitors but predicting them from somatic mutations is a formidable challenge
  • Overview of approach to build better vaccine cocktails.
  • Understand integrated genomics and cell-based solutions in the cancer immunotherapy space, including application of whole transcriptome analysis to characterize the tumor microenvironment and biomarker discovery approaches to predict patient response.

Leveraging the advantages of viral recognition as a cancer immunotherapy

  • Immunomic is addressing the challenges in I-O by applying our proven UNITE technology platform
  • LAMP-based nucleic acid immunotherapies have the potential to broaden the current use of cancer immunotherapy by complementing approved and investigational approaches.
  • LAMP-based nucleic acid immunotherapy has potential as cancer immunotherapy in two general ways:
    • Activation of the immune system against highly immunogenic tumor types, potentially amplifying the response seen with checkpoint inhibitors
    • Creation of a new, robust immune response to tumor types that don’t otherwise provoke an immune reaction, by reconfiguring a critical component of our immune system
  • Several discovery stage programs for virally driven cancers including MCC, NPC/Gastric and HCC. INDs to be filed for these programs in 2019.
Clinical Trials

Personalized immunotherapy gambit

Dr Maurizio Zanetti, Professor of Medicine Moores Cancer Center, University of California San Diego

Networking Lunch & Poster Session

Dr Peter Hotez

Lunchtime presentation & book signing: “Vaccines did not cause Rachel’s Autism”

Vaccine Development

A live attenuated pertussis vaccine to prevent disease, colonization and transmission

  • Why we need aB. pertussisvaccine that induces potentmucosal immunity
  • Relationship between colonizing nasopharyngeal infection and disease
  • Mechanism of action for a live attenuated intranasal vaccine
  • Non-human primate challenge model data
  • Clinical study results

Next generation platform for the development of personalized synthetic cancer vaccines

  • Development of vaccine platform from concept to delivery
    • Bioinformatic immunogen design, use of long peptides and heat shock proteins
  • Challenges of working with peptides
  • Selecting the correct mutations in each patient
  • Parallel approach to selecting neoantigens represented by abnormal post-translational modifications
  • Potential for combination therapy
Vaccine Development

Pertussis and Pertussis vaccines; mistakes made during a 112 year odyssey and what some of those mistakes bode for the future

  • During the 20th century, B. pertussis was extensively studied in animal model systems and many “toxins” and protective antigens were described.
  • DTaP vaccines were developed and put into general use in the USA in 1997.
  • During the last 13 years, major pertussis epidemics have occurred in the USA due to deficiencies in DTaP vaccines.
  • Two of the deficiencies are the small number of antigens and the type of cellular immune response.
  • The small number of antigens leads to linked-epitope suppression.
  • Because of linked-epitope suppression, all children who were primed by DTaP vaccines will be more susceptible to pertussis throughout their lifetimes.

Overcoming tumor immune suppression using a novel retroviral replicating vector

  • Pre-clinical data: observations to support immune mediated mechanism of action
  • Phase 1 data in recurrent high-grade glioma: durable complete responses seen in dose escalation studies
  • Clinical Development: Food and Drug Administration Breakthrough Therapy Designation, European Medicines Agency’s PRIME designation and Phase 3 trial in recurrent glioblastoma and anaplastic astrocytoma
  • Updates in studies for solid tumors

Mosquito-Borne Diseases

T-cell therapies

Infectious diseases

Vaccine Development

Updates in the clinical development of a chikungunya vaccine

  • Trends in chikungunya epidemiology
  • VLP vaccine technology
  • Updates in phase 2 clinical trials

Afternoon Networking Break

Vaccine Development

Panel: Is there a future for arbovirus vaccines?

  • What is the current landscape for dengue, zika and other arbovirus vaccines?
  • Which other arboviruses should be prioritized for vaccine development or for improvements of the existing vaccine(s)?
  • What might emerging arboviruses look like and what improvements are needed in current vaccines?
  • Finding a better way to evaluate these vaccines before going into phase 3 trials.
  • Using human protection models to discover the keys to eliciting a protective immune response
  • How will the immune response to one virus affect that of another?
  • What are the challenges to funding and commercializing arbovirus vaccines?

Strategies for the development of safer and more effective CAR-T therapies

  • General strategies for CAR-T cell control
  • Defining small molecule vs antibody-based targeting – why we use Ab-based targeting.
  • Deep dive into the technicalities of designing these switches to control different targets
  • Universality of the platform and potential for use in solid tumors.
Clinical Trials

A year of substantial progress: clinical development of TB vaccine candidates

  • A TB vaccine is urgently needed to meet the WHO and UN goals for ending TB
  • Update on status of the overall pipeline of TB vaccine candidates
  • Substantial progress was demonstrated by the results of two efficacy trials of vaccine candidates
  • Implications of the efficacy trial results and takeaways for future candidates and trials
Clinical Trials

Clinical development of a subunit based congenital CMV vaccine

  • Vaccine development for CMV: High unmet medical need
  • CMV vaccine development at GSK, past and present
  • Critical challenges facing CMV vaccine developers

Chair closing remarks of day one followed by onsite networking drinks reception and meet & greet with key speakers

last published: 22/Nov/18 11:45 GMT



Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

To speak:
Lauren Sheppard
+44 (0)207 092 1211